{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:18Z","timestamp":1794007458786,"version":"4.8.0"},"reference-count":85,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Dementia with Lewy Bodies (DLB) is a common form of cognitive neurodegenerative disease. Only one third of patients are correctly diagnosed due to the clinical similarity mainly with Alzheimer\u2019s disease (AD). In this review, we evaluate the interest of different biomarkers: cerebrospinal fluid (CSF), brain MRI, FP-CIT SPECT, MIBG SPECT, PET by focusing more specifically on differential diagnosis between DLB and AD. FP-CIT SPECT is of high interest to discriminate DLB and AD, but not at the prodromal stage (i.e., MCI). MIBG SPECT with decreased cardiac sympathetic activity, perfusion SPECT with occipital hypoperfusion, FDG PET with occipital hypometabolism and cingulate island signs are of interest at the dementia stage but with a lower validity. Brain MRI has shown differences in group study with lower grey matter concentration of the Insula in prodromal DLB, but its interest in clinical routines is not demonstrated. Concerning CSF biomarkers, many studies have already examined the relevance of AD biomarkers but also alpha-synuclein assays in DLB, so we will focus as comprehensively as possible on other biomarkers (especially those that do not appear to be directly related to synucleinopathy) that may be of interest in the differential diagnosis between AD and DLB. Furthermore, we would like to highlight the growing interest in CSF synuclein RT-QuIC, which seems to be an excellent discrimination tool but its application in clinical routine remains to be demonstrated, given the non-automation of the process.<\/jats:p>","DOI":"10.3390\/ijms23126371","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T02:25:33Z","timestamp":1654827933000},"page":"6371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-3191","authenticated-orcid":false,"given":"Olivier","family":"Bousiges","sequence":"first","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, 67000 Strasbourg, France"},{"name":"Team IMIS, ICube Laboratory UMR 7357 and FMTS (F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg), University of Strasbourg and CNRS, 67000 Strasbourg, France"},{"name":"CM2R (Research and Resources Memory Centre), Geriatrics Department, Day Hospital and Cognitive-Behavioral Unit University Hospitals of Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-3247","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[{"name":"Team IMIS, ICube Laboratory UMR 7357 and FMTS (F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg), University of Strasbourg and CNRS, 67000 Strasbourg, France"},{"name":"CM2R (Research and Resources Memory Centre), Geriatrics Department, Day Hospital and Cognitive-Behavioral Unit University Hospitals of Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age Ageing"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00005072-196104000-00007","article-title":"Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion","volume":"20","author":"Okazaki","year":"1961","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/alzrt274","article-title":"The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis","volume":"6","author":"Donaghy","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived alpha-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Gelders","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-017-0242-1","article-title":"Cognitive profile in prodromal dementia with Lewy bodies","volume":"9","author":"Kemp","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","article-title":"Accuracy of clinical diagnosis of dementia with Lewy bodies: A systematic review and meta-analysis","volume":"89","author":"Rizzo","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-009-5324-y","article-title":"Low sensitivity in clinical diagnoses of dementia with Lewy bodies","volume":"257","author":"Nelson","year":"2010","journal-title":"J. Neurol."},{"key":"ref_15","first-page":"189","article-title":"Lewy body dementia: Therapeutic propositions according to evidence based medicine and practice","volume":"17","author":"Verny","year":"2019","journal-title":"Geriatr. Psychol. Neuropsychiatr. Vieil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","article-title":"Neuroleptic sensitivity in patients with senile dementia of Lewy body type","volume":"305","author":"McKeith","year":"1992","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cca.2018.11.027","article-title":"Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies","volume":"490","author":"Bousiges","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","article-title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage","volume":"89","author":"Bousiges","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wennstrom, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Bostrom, F., Hansson, O., and Nielsen, H.M. (2013). Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053250"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","article-title":"Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia","volume":"9","author":"Chiasserini","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Law, Z.K., Todd, C., Mehraram, R., Schumacher, J., Baker, M.R., LeBeau, F.E.N., Yarnall, A., Onofrj, M., Bonanni, L., and Thomas, A. (2020). The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies\u2014A Systematic Review. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090616"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Blanc, F., Colloby, S.J., Philippi, N., de Petigny, X., Jung, B., Demuynck, C., Phillipps, C., Anthony, P., Thomas, A., and Bing, F. (2015). Cortical Thickness in Dementia with Lewy Bodies and Alzheimer\u2019s Disease: A Comparison of Prodromal and Dementia Stages. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127396"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1038\/s41598-017-08667-7","article-title":"Insular atrophy at the prodromal stage of dementia with Lewy bodies: A VBM DARTEL study","volume":"7","author":"Roquet","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-016-0198-6","article-title":"Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"8","author":"Blanc","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.parkreldis.2021.03.011","article-title":"Hippocampal and insula volume in mild cognitive impairment with Lewy bodies","volume":"86","author":"Firbank","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000003371","article-title":"Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment","volume":"87","author":"Kantarci","year":"2016","journal-title":"Neurology"},{"key":"ref_28","unstructured":"Blanc, F., Schulz, I., Mondino, M., Gobin, M.S.I., Gudewiez, R., Loureiro De Sousa, P., Philippi, N., Baloglu, S., Cretin, B., and Demuynck, C. (2019). Atrophy of insulae and hippocampi in prodromal dementia with Lewy bodies and Alzheimer\u2019s Disease: Visual assessment. ADPD."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/brain\/awn298","article-title":"Medial temporal lobe atrophy on MRI differentiates Alzheimer\u2019s disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis","volume":"132","author":"Burton","year":"2009","journal-title":"Brain A J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/brain\/aww005","article-title":"MRI visual rating scales in the diagnosis of dementia: Evaluation in 184 post-mortem confirmed cases","volume":"139","author":"Harper","year":"2016","journal-title":"Brain A J. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-180687","article-title":"Loss of Swallow Tail Sign on Susceptibility-Weighted Imaging in Dementia with Lewy Bodies","volume":"67","author":"Rizzo","year":"2019","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3174\/ajnr.A5274","article-title":"MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?","volume":"38","author":"Shams","year":"2017","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_33","first-page":"196","article-title":"Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?","volume":"15","author":"Blanc","year":"2017","journal-title":"Geriatr. Psychol. Neuropsychiatr. Vieil."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/brain\/aws211","article-title":"Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias","volume":"135","author":"Colloby","year":"2012","journal-title":"Brain A J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/jnnp-2012-302577","article-title":"Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT","volume":"83","author":"Morgan","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","article-title":"Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: An updated systematic review and Bayesian latent class model meta-analysis","volume":"47","author":"Nihashi","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1017\/S0033291718000995","article-title":"Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies","volume":"49","author":"Thomas","year":"2019","journal-title":"Psychol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/WNL.56.5.643","article-title":"Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD","volume":"56","author":"Lobotesis","year":"2001","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00259-002-0919-x","article-title":"Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies","volume":"29","author":"Pasquier","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00259-005-1921-x","article-title":"Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"33","author":"Hanyu","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12149-017-1181-4","article-title":"Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease using brain perfusion SPECT","volume":"31","author":"Imabayashi","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"568438","DOI":"10.3389\/fneur.2020.568438","article-title":"Differentiating Mild Cognitive Impairment, Alzheimer\u2019s Disease, and Dementia with Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT","volume":"11","author":"Kanetaka","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2967\/jnumed.114.143347","article-title":"18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias","volume":"55","author":"Firbank","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(97)00713-1","article-title":"Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer\u2019s disease: A comparative study using positron emission tomography","volume":"235","author":"Imamura","year":"1997","journal-title":"Neurosci. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-\u03b2-CIT SPECT for Diagnosis of Dementia with Lewy Bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12149-016-1076-9","article-title":"Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies","volume":"30","author":"Iizuka","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2967\/jnumed.116.179903","article-title":"(18)F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies","volume":"58","author":"Whitwell","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Korat, \u0160., Bidesi, N.S.R., Bonanno, F., Di Nanni, A., Ho\u00e0ng, A.N.N., Herfert, K., Maurer, A., Battisti, U.M., Bowden, G.D., and Thonon, D. (2021). Alpha-Synuclein PET Tracer Development\u2014An Overview about Current Efforts. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090847"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","article-title":"[(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates","volume":"48","author":"Kuebler","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain A J. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Yoshita, M., Arai, H., Arai, H., Arai, T., Asada, T., Fujishiro, H., Hanyu, H., Iizuka, O., Iseki, E., and Kashihara, K. (2015). Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: A multicenter study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120540"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2016.04.026","article-title":"Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer\u2019s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework","volume":"52","author":"Sonni","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2801","DOI":"10.1212\/WNL.0000000000012060","article-title":"Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment with Lewy Bodies","volume":"96","author":"Roberts","year":"2021","journal-title":"Neurology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/acn3.50897","article-title":"alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"6","author":"Bongianni","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"McGrowder, D.A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., and Latore, L. (2021). Cerebrospinal Fluid Biomarkers of Alzheimer\u2019s Disease: Current Evidence and Future Perspectives. Brain Sci., 11.","DOI":"10.3390\/brainsci11020215"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-019-44173-8","article-title":"Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"9","author":"Alcolea","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-015-0145-y","article-title":"Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients","volume":"7","author":"Wennstrom","year":"2015","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3233\/JAD-210147","article-title":"Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer\u2019s and Lewy Body Diseases","volume":"82","author":"Lourenco","year":"2021","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_65","first-page":"536538","article-title":"Cerebrospinal fluid biomarkers for dementia with lewy bodies","volume":"2010","author":"Monteith","year":"2010","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3233\/JAD-191153","article-title":"Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders","volume":"73","author":"Gmitterova","year":"2020","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","article-title":"Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease","volume":"10","author":"Duits","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jnc.12331","article-title":"CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer\u2019s disease and dementia with Lewy bodies","volume":"127","author":"Luo","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zou, K., Abdullah, M., and Michikawa, M. (2020). Current Biomarkers for Alzheimer\u2019s Disease: From CSF to Blood. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030085"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-020-00388-2","article-title":"Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: A proteomic approach","volume":"15","author":"Vergouw","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Van Steenoven, I., Noli, B., Cocco, C., Ferri, G.L., Oeckl, P., Otto, M., Koel-Simmelink, M.J.A., Bridel, C., van der Flier, W.M., and Lemstra, A.W. (2019). VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194674"},{"key":"ref_72","first-page":"e12179","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease","volume":"13","author":"Nilsson","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Boiten, W.A., van Steenoven, I., Xiao, M., Worley, P.F., Lemstra, A.W., and Teunissen, C.E. (2020). Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells, 10.","DOI":"10.3390\/cells10010038"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1700131","DOI":"10.1002\/prca.201700131","article-title":"A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer\u2019s Disease","volume":"12","author":"Brinkmalm","year":"2018","journal-title":"PROTEOMICS Clin. Appl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/WAD.0000000000000328","article-title":"VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion from MCI to AD","volume":"33","author":"Llano","year":"2019","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1210\/er.2010-0027","article-title":"The extended granin family: Structure, function, and biomedical implications","volume":"32","author":"Bartolomucci","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jchemneu.2011.05.007","article-title":"VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers","volume":"42","author":"Ferri","year":"2011","journal-title":"J. Chem. Neuroanat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0896-6273(03)00463-X","article-title":"Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity","volume":"39","author":"Xu","year":"2003","journal-title":"Neuron"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0896-6273(00)80782-5","article-title":"Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp","volume":"23","author":"Xu","year":"1999","journal-title":"Neuron"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharmthera.2009.05.006","article-title":"30 years of dynorphins\u2014New insights on their functions in neuropsychiatric diseases","volume":"123","author":"Schwarzer","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00018-011-0844-x","article-title":"The dynorphin\/kappa-opioid receptor system and its role in psychiatric disorders","volume":"69","author":"Tejeda","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WAD.0000000000000414","article-title":"Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts","volume":"35","author":"Armstrong","year":"2021","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3182a2cbd1","article-title":"Risk factors for dementia with Lewy bodies: A case-control study","volume":"81","author":"Boot","year":"2013","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:25:33Z","timestamp":1760138733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":85,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23126371"],"URL":"https:\/\/doi.org\/10.3390\/ijms23126371","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}